Efficacy and safety of the combined oral contraceptive ethinylestradiol/drospirenone (Yasmin) in healthy Chinese women: a randomized, open-label, controlled, multicentre trial
- PMID: 20201608
- DOI: 10.1007/BF03256908
Efficacy and safety of the combined oral contraceptive ethinylestradiol/drospirenone (Yasmin) in healthy Chinese women: a randomized, open-label, controlled, multicentre trial
Abstract
To evaluate and compare the contraceptive efficacy, bleeding pattern, side effects and other positive effects of a combined oral contraceptive (COC) containing drospirenone (DRSP) [Yasmin] with those of a COC containing desogestrel (DSG) in healthy Chinese women. This was a randomized, open-label, controlled, multicentre study of 768 healthy Chinese women requiring contraception. The subjects were randomized to ethinylestradiol (EE) 30 microg/DRSP 3 mg (n = 573) or EE 30 microg/ DSG 150 microg (n = 195), at a ratio of 3 : 1. Each individual was treated for 13 cycles. Further visits were required at cycle 4, cycle 7, cycle 10 and cycle 13 of treatment. Weight, height and body mass index were evaluated at each visit. The Menstrual Distress Questionnaire (MDQ) was administered at baseline, visit 3 (cycle 7) and visit 5 (after cycle 13). Baseline characteristics were similar between the two groups (p > 0.05). The Pearl Index (method failure) for EE/DRSP was 0.208 per 100 women-years, which was lower than that for EE/DSG (0.601 per 100 women-years). There were no significant differences between the treatment groups with regard to bleeding patterns. According to the MDQ subscale, improvements in water retention and increases in appetite during the intermenstrual period and in water retention and general well-being during the menstrual period in the EE/DRSP group (-0.297, -0.057, 0.033 and 0.150, respectively) were significantly improved compared with the EE/DSG group (-0.108, 0.023, 0.231 and -0.023, respectively) [all p < 0.05]. Other values that improved in both groups, particularly improvement in breast pain and tenderness and skin condition, were more evident in the EE/DRSP group (18.0%, 89/494; 12.6%, 62/494) than in the EE/DSG group (11.3%, 19/168; 5.4%, 9/168). Mean weight increased in the EE/DSG group (0.57 kg) while there was a significant decrease in mean weight (-0.28 kg) in the EE/DRSP group (p < 0.01). Both EE/DRSP and EE/DSG have good contraceptive efficacy and a comparable bleeding pattern. EE/DRSP had a more favourable effect on weight and premenstrual symptoms than EE/DSG.
Similar articles
-
Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive.Treat Endocrinol. 2003;2(1):49-70. doi: 10.2165/00024677-200302010-00005. Treat Endocrinol. 2003. PMID: 15871554 Review.
-
Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallel-group, multicentre study.Clin Drug Investig. 2010;30(5):325-36. doi: 10.2165/11535450-000000000-00000. Clin Drug Investig. 2010. PMID: 20384388 Clinical Trial.
-
A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles.Contraception. 2004 Apr;69(4):271-8. doi: 10.1016/j.contraception.2003.11.003. Contraception. 2004. PMID: 15033400 Clinical Trial.
-
Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive.Contraception. 2009 Nov;80(5):445-51. doi: 10.1016/j.contraception.2009.03.013. Epub 2009 May 9. Contraception. 2009. PMID: 19835718 Clinical Trial.
-
Experiences with Yasmin: the acceptability of a novel oral contraceptive and its effect on well-being.Eur J Contracept Reprod Health Care. 2002 Dec;7 Suppl 3:35-41; discussion 42-3. Eur J Contracept Reprod Health Care. 2002. PMID: 12659405 Review.
Cited by
-
Does the presence of coexisting diseases modulate the effectiveness of a low-dose estrogen/progestin, ethinylestradiol/drospirenone combination tablet in dysmenorrhea? Reanalysis of two randomized studies in Japanese women.Int J Womens Health. 2014 Dec 2;6:989-98. doi: 10.2147/IJWH.S70935. eCollection 2014. Int J Womens Health. 2014. PMID: 25506249 Free PMC article.
-
Oral contraceptives containing drospirenone for premenstrual syndrome.Cochrane Database Syst Rev. 2023 Jun 23;6(6):CD006586. doi: 10.1002/14651858.CD006586.pub5. Cochrane Database Syst Rev. 2023. PMID: 37365881 Free PMC article. Review.
-
Hormonal contraceptive use and depressive symptoms: systematic review and network meta-analysis of randomised trials.BJPsych Open. 2021 Jun 8;7(4):e110. doi: 10.1192/bjo.2021.64. BJPsych Open. 2021. PMID: 34099098 Free PMC article.
-
Effects of continuous-combined oral drospirenone- estradiol on blood pressure, body weight & lipid profile in early menopausal women.Indian J Med Res. 2021 Jun;154(6):857-865. doi: 10.4103/ijmr.IJMR_478_20. Indian J Med Res. 2021. PMID: 35662091 Free PMC article.
-
Combination contraceptives: effects on weight.Cochrane Database Syst Rev. 2014 Jan 29;2014(1):CD003987. doi: 10.1002/14651858.CD003987.pub5. Cochrane Database Syst Rev. 2014. PMID: 24477630 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources